Product Details
Niraparib for Tablets BP
Product Name
:
Niraparib for Tablets BP
Brand Name
:
VERNIRA
Available Strength
:
300 mg
Packing
:
60 Tablets
Pack Insert/Leaflet
:
According To Your Needs
These film-coated tablets meet British Pharmacopoeia standards, supporting maintenance treatment for ovarian cancer. Oncologists prescribe Niraparib following a response to platinum-based chemotherapy, regardless of BRCA mutation status.
Niraparib BP (300 mg) is a PARP inhibitor that blocks DNA repair in cancer cells with existing DNA-repair deficiencies, leading to cell death. As a result, it helps extend the period before disease progression. Because of this targeted mechanism, oncology specialists prescribe it under close supervision as part of an individualized maintenance regimen. Therefore, hospitals and oncology clinics restrict its use to patients under specialist care.
Key Features
- Meets BP (British Pharmacopoeia) standards for consistent quality
- Delivers targeted PARP inhibition for ovarian cancer maintenance therapy
- Ensures accurate, validated dosing in every batch
- Manufactured under GMP-compliant, high-alert medication handling protocols
- Intended strictly for use under oncologist supervision
- Restricted to hospital, oncology clinic, and specialist institutional supply